Research brief · Growth Hormone
CJC-1295 no DAC + Ipamorelin
GHRH + selective ghrelin-agonist research blend for pulsatile GH release studies.
Class
GHRH analogue + selective ghrelin-receptor agonist blend
Half-life
~30 min (CJC-1295 no DAC) / ~2 h (ipamorelin)
Studied in
Pulsatile GH-release kinetics, somatotroph synergy, sleep-EEG research.
What it is
This blend pairs CJC-1295 without DAC (Mod GRF 1-29) — a short-acting GHRH analogue — with ipamorelin, a selective ghrelin-receptor (GHS-R1a) agonist. In research the combination is used to study amplified, pulsatile GH release without the cortisol or prolactin rise associated with older secretagogues.
Mechanism studied
Synergistic activation of GHRH and GHS-R1a receptors for amplified, pulsatile GH release in research models.
Research notes
- Reproduces a more physiological GH pulse profile than either peptide alone.
- Ipamorelin's selectivity keeps cortisol and prolactin endpoints clean in comparative work.
Before sourcing any material
- Confirm a lot-matched third-party certificate of analysis (HPLC purity and mass-spectrometry identity).
- Check the stated peptide content per vial, not just the gross vial mass.
- Plan reconstitution volumes first so the vial size matches your protocol.
- Verify what is lawful in your jurisdiction — these are in-vitro research reagents, not medicines.